Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

MET variant as a prognostic marker in clear cell renal cell carcinoma

2014 Genitourinary Cancers Symposium

30 Jan - 1 Feb 2014

Published: 31 Jan 2014

Views: 4177

Rating:

Save

Dr Ari Hakimi - Memorial Sloan-Kettering Cancer Center, New York, USA

Dr Ari Hakimi of the Memorial Sloan-Kettering Cancer Center, New York, USA, at the ASCO GU congress 2014 discusses the MET variant as a prognostic marker in clear cell renal cell carcinoma (ccRCC) and its future implications.

Related Videos

ASCO GU 2026: Updates in metastatic prostate cancer

Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo', Universidad de Buenos Aires, Argentina

ASCO GU 2026: Updates in metastatic prostate cancer ( Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo', Universidad de Buenos Aires, Argentina )

ESMO 2024: Optimising the personalisation of prostate cancer treatment

Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg

ESMO 2024: Optimising the personalisation of prostate cancer treatment ( Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg )

ERBB2 amplifications across sex, race, and cancer types studied to guide HER2 therapies

Dr Marc Machaalani - Dana-Farber Cancer Institute, Boston, USA

ERBB2 amplifications across sex, race, and cancer types studied to guide HER2 therapies ( Dr Marc Machaalani - Dana-Farber Cancer Institute, Boston, USA )

Best practice in HRRm testing in patients with metastatic prostate cancer

Prof Martin Schostak, Dr Alexander Wyatt, Prof Charles Ryan and Dr Emmanuel Antonarakis

Best practice in HRRm testing in patients with metastatic prostate cancer ( Prof Martin Schostak, Dr Alexander Wyatt, Prof Charles Ryan and Dr Emmanuel Antonarakis )

Looking at real world evidence on PSA testing in prostate cancer

Dr Friederike Schlurmann, Prof Boris Hadaschik and Prof Karim Fizazi

Looking at real world evidence on PSA testing in prostate cancer ( Dr Friederike Schlurmann, Prof Boris Hadaschik and Prof Karim Fizazi )

OncoAlert round up July 28th to August 3rd, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert round up July 28th to August 3rd, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

PHERGain trial ID's early breast cancer cases that benefit from dual HER2 blockade without chemo

Dr Javier Cortes - Vall d’Hebron University Hospital, Barcelona, Spain

PHERGain trial ID's early breast cancer cases that benefit from dual HER2 blockade without chemo ( Dr Javier Cortes - Vall d’Hebron University Hospital, Barcelona, Spain )

AI-derived digital pathology-based biomarker predicts benefit of long-term ADT with RT in localised high-risk prostate cancer

Prof Andrew Armstrong - Duke University, Durham, USA

AI-derived digital pathology-based biomarker predicts benefit of long-term ADT with RT in localised high-risk prostate cancer ( Prof Andrew Armstrong - Duke University, Durham, USA )

More from ecancer